Skip to content

Clinical observation of fire needle combined with halometasone cream in the treatment of acral vitiligo

Clinical observation of fire needle combined with halometasone cream in the treatment of acral vitiligo

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045872
Enrollment
Unknown
Registered
2021-04-25
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

Sponsors

Dermatology Hospital,Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria and consensus on diagnosis and treatment, meet the criteria for acral typing, meet the criteria for stable stage staging, and be stable for at least 6 months; 2. Aged 18 to 60 years, gender is not limited, the course of disease is less than 5 years; 3. There is no pigment island and self-healing tendency in leukoplakia; 4. The skin lesion area accounts for <= 1% of the body surface area; 5. Have not received immunosuppressive agents, glucocorticoids, non-steroidal anti-inflammatory drugs and other systemic treatments within 3 months, and have not received local treatments within 1 month; 6. Patients who agree to and abide by the diagnosis and treatment plan, voluntarily sign an informed consent form, and cooperate in taking photos before and after treatment.

Exclusion criteria

Exclusion criteria: 1. Fainted needles, scarred physique, or extremely fearful of fire needles; 2. Patients who are allergic to halometasone cream; 3. Patients with combined serious diseases, such as serious heart, brain, liver, kidney, hematopoietic system and other system diseases, or patients with malignant tumors; 4. Female patients who are pregnant, breastfeeding or planning to become pregnant within six months; 5. Partial skin lesions have redness, swelling, damage or infection.

Design outcomes

Primary

MeasureTime frame
vitiligo area;

Countries

China

Contacts

Public ContactLuo Guangpu

Southern Medical University

102931@163.com+86 13926166004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026